{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:32:24Z","timestamp":1757611944749,"version":"3.44.0"},"reference-count":152,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Plasma cell disorders present challenges in phenotypic determination, as they range from monoclonality of plasma cells to multiple myeloma and plasma cell leukemia. According to World Health Organization guidelines, no single aberrant marker is recognized to be uniquely linked to multiple myeloma. The absence of a preset marker panel proven to account for multiple myeloma diversity causes difficulties in diagnosis and clinical research; therefore, the need to create a well-defined panel is urgently needed. For this manuscript, we reviewed the literature on the phenotypic and immunological features that lead to incomplete information and problems in immunophenotyping. We offer proposed solutions for identifying the suitable markers and technology to fill this gap, by using a well-defined gating strategy in a high-dimensional mass cytometry (CyTOF) panel and by next-generation flow cytometry. We analyze pitfalls, starting with sample preparation, selection of the marker panel, gating strategy, cleaning up events, quality control, troubleshooting and validation, and finally, analysis of data. We advance a comprehensive protocol that allows for a detailed analysis of the immunophenotype of myeloma cells. By identifying aberrant markers in the panel, we may be able to facilitate diagnosis and prognosis, ultimately influencing the choice of therapeutic regimens and patients\u2019 overall survival.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1642609","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T05:32:35Z","timestamp":1756963955000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Dissecting immunophenotypic diversity in multiple myeloma via mass cytometry: a call for harmonized gating strategies"],"prefix":"10.3389","volume":"16","author":[{"given":"Mahmoud","family":"Singer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milad","family":"Moloudizargari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Pichiorri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00137","article-title":"Immunophenotype of normal and myelomatous plasma-cell subsets","volume":"5","author":"Robillard","year":"2014","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.3324\/haematol.2017.163766","article-title":"The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma","volume":"102","author":"Mikulasova","year":"2017","journal-title":"Haematologica"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-270140","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies","volume":"117","author":"Korde","year":"2011","journal-title":"Blood J Am Soc Hematol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3390\/biomedicines9111637","article-title":"LncRNAs LY86-AS1 and VIM-AS1 distinguish plasma cell leukemia patients from multiple myeloma patients","volume":"9","author":"B\u00fatov\u00e1","year":"2021","journal-title":"Biomedicines"},{"key":"B5","article-title":"Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma","volume":"110","author":"Gonz\u00e1lez","year":"2007","journal-title":"Blood J Am Soc Hematology."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1551536","article-title":"Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study","volume":"60","author":"Campa","year":"2019","journal-title":"Leukemia lymphoma."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1159\/000520312","article-title":"Multiple myeloma: molecular pathogenesis and disease evolution","volume":"44","author":"Heider","year":"2021","journal-title":"Oncol Res Treat"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204641","article-title":"Chromosome translocations in multiple myeloma","volume":"20","author":"Bergsagel","year":"2001","journal-title":"Oncogene"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cancergencyto.2010.11.002","article-title":"The prognostic significance of cytogenetics and molecular profiling in multiple myeloma","volume":"204","author":"Sawyer","year":"2011","journal-title":"Cancer Genet"},{"key":"B10","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-19983-2_8","article-title":"Immunoglobulin and MYC rearrangements in multiple myeloma pathogenesis","volume-title":"Chromosomal Translocations and Genome Rearrangements in Cancer","author":"Bergsagel","year":"2015"},{"key":"B11","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/bjh.14649","article-title":"Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma","volume":"178","author":"Dutta","year":"2017","journal-title":"Br J Haematology."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002524","article-title":"The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models","volume":"4","author":"Cho","year":"2020","journal-title":"Blood Adv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174249","article-title":"T-cell-based cellular immunotherapy of multiple myeloma: current developments","volume":"14","author":"Simmons","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2021.04.005","article-title":"Antigen loss after targeted immunotherapy in hematological Malignancies","volume":"41","author":"Zhou","year":"2021","journal-title":"Clin Lab Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2017.1393668","article-title":"CAR T cell therapy for multiple myeloma: where are we now and where are we headed","volume":"59","author":"Ghosh","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061353","article-title":"Immune system alterations in multiple myeloma: molecular mechanisms and therapeutic strategies to reverse immunosuppression","volume":"13","author":"Diaz-Tejedor","year":"2021","journal-title":"Cancers (Basel)."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e2021043","DOI":"10.4084\/MJHID.2021.043","article-title":"Aberrant acquisition of t-cell associated markers in plasma cell neoplasms: an aggressive disease with extramedullary involvement and very short survival","volume":"13","author":"Soliman","year":"2021","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41408-024-01051-5","article-title":"CD56 expression predicts response to Daratumumab-based regimens","volume":"14","author":"Robinette","year":"2024","journal-title":"Blood Cancer J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"SCI","DOI":"10.1182\/blood.V124.21.SCI-50.SCI-50","article-title":"Dual face of immune microenvironment in myeloma","volume":"124","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/cancers13040625","article-title":"The immune microenvironment in multiple myeloma: friend or foe","volume":"13","author":"Lopes","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/0192623317736742","article-title":"Immunophenotyping: application to safety assessment","volume":"45","author":"Wang","year":"2017","journal-title":"Toxicol Pathol"},{"volume-title":"Immunophenotyping","year":"2025","author":"Herold","key":"B23"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.3390\/cancers15143687","article-title":"Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future","volume":"15","author":"Medina-Herrera","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12943-023-01783-1","article-title":"Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies","volume":"22","author":"Huang","year":"2023","journal-title":"Mol Cancer."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0866","article-title":"New developments in diagnosis, prognosis, and assessment of response in multiple myeloma","volume":"22","author":"Landgren","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2015.1.272","article-title":"Evolving diagnostic criteria for multiple myeloma","volume":"2015","author":"Rajkumar","year":"2015","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147470","article-title":"Next-generation biomarkers in multiple myeloma: understanding the molecular basis for potential use in diagnosis and prognosis","volume":"22","author":"Soliman","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e052759","DOI":"10.1136\/bmjopen-2021-052759","article-title":"Clinical features and diagnosis of multiple myeloma: a population-based cohort study in primary care","volume":"11","author":"Seesaghur","year":"2021","journal-title":"BMJ Open"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1589-9","article-title":"FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4+ T regulatory cells","volume":"63","author":"Braga","year":"2014","journal-title":"Cancer Immunology Immunother"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2010.036814","article-title":"Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma","volume":"96","author":"Atanackovic","year":"2011","journal-title":"Haematologica"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.2013.163.issue-5","article-title":"Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma","volume":"163","author":"Hajek","year":"2013","journal-title":"Br J haematology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.v12.3","article-title":"A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma","volume":"12","author":"Tang","year":"2023","journal-title":"Cancer Med"},{"key":"B35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Flores-Montero","year":"2016","journal-title":"Cytometry Part B: Clin Cytometry."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217550","article-title":"The immunomodulatory role of tumor Syndecan-1 (CD138) on ex vivo tumor microenvironmental CD4+ T cell polarization in inflammatory and non-inflammatory breast cancer patients","volume":"14","author":"Saleh","year":"2019","journal-title":"PLoS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"Van de Donk","year":"2018","journal-title":"Blood J Am Soc Hematol"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023021570","article-title":"A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-\u03b3\u2013induced CD38 expression","volume":"143","author":"Murtadha","year":"2024","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1589","article-title":"A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies","volume":"74","author":"Green","year":"2014","journal-title":"Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1641196","article-title":"B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma","volume":"19","author":"Tai","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/ijlh.v43.s1","article-title":"Evaluation of measurable residual disease in multiple myeloma by multiparametric flow cytometry: Current paradigm, guidelines, and future applications","volume":"43","author":"Soh","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"B42","article-title":"Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders","volume":"78","author":"Paiva","year":"2010","journal-title":"Cytometry Part B: Clin Cytometry."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2010.09.002","article-title":"Immunophenotyping in multiple myeloma and related plasma cell disorders","volume":"23","author":"Kumar","year":"2010","journal-title":"Best Pract Res Clin haematology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4361264","article-title":"Cost-effectiveness of anti-BCMA chimeric antigen receptor T cell therapy in relapsed\/ refractory multiple myeloma","volume":"30","author":"Yamamoto","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B45","doi-asserted-by":"publisher","first-page":"100050","DOI":"10.1016\/j.modpat.2022.100050","article-title":"A novel BCMA immunohistochemistry assay reveals a heterogenous and dynamic BCMA expression profile in multiple myeloma","volume":"36","author":"Zhang","year":"2023","journal-title":"Mod Pathol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.3390\/cells9122666","article-title":"Novel insights in anti-CD38 therapy based on CD38-receptor expression and function: the multiple myeloma model","volume":"9","author":"Zannetti","year":"2020","journal-title":"Cells"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.3390\/ijms20051248","article-title":"The impact of tumor heterogeneity on diagnostics and novel therapeutic strategies in multiple myeloma","volume":"20","author":"Rasche","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.3390\/jcm11102913","article-title":"CD24 is a prognostic marker for multiple myeloma progression and survival","volume":"11","author":"Gross Even-Zohar","year":"2022","journal-title":"J Clin Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403823","article-title":"CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations","volume":"19","author":"Kumar","year":"2005","journal-title":"Leukemia"},{"key":"B50","article-title":"MPC-1\u2013 CD49e\u2013 immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas","volume":"105","author":"Fujii","year":"1999","journal-title":"Br J haematology."},{"key":"B51","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-019-0519-4","article-title":"Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination","volume":"34","author":"Akhmetzyanova","year":"2020","journal-title":"Leukemia"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880435","article-title":"Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions","volume":"14","author":"Bayer-Garner","year":"2001","journal-title":"Mod Pathol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136824","article-title":"A novel CD138-targeting monoclonal antibody induces potent myeloma killing and further synergizes with IMiDs or bortezomib in in vitro and in vivo preclinical models of human multiple myeloma","volume":"136","author":"Yu","year":"2020","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2013.213884","article-title":"Unexpected test results in a patient with multiple myeloma","volume":"60","author":"Jelinek","year":"2014","journal-title":"Clin Chem"},{"key":"B55","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1046\/j.1365-2141.1997.72653.x","article-title":"Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage","volume":"97","author":"Rawstron","year":"1997","journal-title":"Br J haematology."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.5045\/kjh.2012.47.4.260","article-title":"Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56\/CD19\/CD138 (CD38)\/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells","volume":"47","author":"Jeong","year":"2012","journal-title":"Korean J Hematology."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13387","article-title":"Adhesion molecule immunophenotype of bone marrow multiple myeloma plasma cells impacts the presence of malignant circulating plasma cells in peripheral blood","volume":"43","author":"Klimien\u0117","year":"2021","journal-title":"Int J Lab Hematology."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.9365","article-title":"Association of CD117 and HLA-DR expression with shorter overall survival and\/or progression-free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation","volume":"16","author":"Wang","year":"2018","journal-title":"Oncol Lett"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216524","article-title":"Dual negativity of CD56 and CD117 links to unfavorable cytogenetic abnormalities and predicts poor prognosis in multiple myeloma","volume":"11","author":"Zheng","year":"2022","journal-title":"J Clin Med"},{"key":"B60","article-title":"The relationship between the expressions of CD33 and CD13 and the prognosis of patients with multiple myeloma","volume":"30","author":"Li","year":"2022","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1574003","article-title":"Clinical effects of CD33 and MPC-1 on the prognosis of multiple myeloma treated with bortezomib","volume":"60","author":"Oka","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B62","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2020.1839653","article-title":"Clinical significance of CD200 expression in newly diagnosed multiple myeloma patients and dynamic changing during treatment","volume":"62","author":"Shi","year":"2021","journal-title":"Leuk Lymphoma."},{"key":"B63","article-title":"Correlation between expression of CD200 and regulatory t cells in multiple myeloma and its significance in prognostic stratification","volume":"24","author":"Zhu","year":"2016","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404445","article-title":"Elevation of soluble CD307 (IRTA2\/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma","volume":"21","author":"Ise","year":"2007","journal-title":"Leukemia"},{"key":"B65","article-title":"Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR-T therapy","volume":"143","author":"Tang","year":"2023","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Sanoja-Flores","year":"2018","journal-title":"Blood Cancer J"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti\u2013PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood J Am Soc Hematology."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2013.10","article-title":"NK cell-based immunotherapy for malignant diseases","volume":"10","author":"Cheng","year":"2013","journal-title":"Cell Mol Immunol"},{"key":"B69","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2004-04-1422","article-title":"NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells","volume":"105","author":"Carbone","year":"2005","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3390\/cancers13020226","article-title":"Alterations of NK cell phenotype in the disease course of multiple myeloma","volume":"13","author":"Pazina","year":"2021","journal-title":"Cancers"},{"key":"B71","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2019000953","article-title":"Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules","volume":"4","author":"Barberi","year":"2020","journal-title":"Blood advances."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/333855a0","article-title":"Expression of the \u03b3-\u03b4 T-cell receptor on intestinal CD8+ intraepithelial lymphocytes","volume":"333","author":"Goodman","year":"1988","journal-title":"Nature"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000024353","article-title":"Antigen recognition by human \u03b3\u03b4 T lymphocytes","volume":"122","author":"Kabelitz","year":"2000","journal-title":"Int Arch Allergy Immunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"119","DOI":"10.7150\/ijbs.7823","article-title":"\u03b3\u03b4 T cells and their potential for immunotherapy","volume":"10","author":"Wu","year":"2014","journal-title":"Int J Biol Sci"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.3390\/cells9081757","article-title":"Engineering the bridge between innate and adaptive immunity for cancer immunotherapy: focus on \u03b3\u03b4 T and NK cells","volume":"9","author":"Morandi","year":"2020","journal-title":"Cells"},{"key":"B76","article-title":"Estimation of gamma-delta-1 T cell receptor (\u03b3\u03b4-1 TCR) expression in bone marrow lymphocyte population in lymphoma Malignum and multiple myeloma","volume":"59","author":"Sowi\u0144ska","year":"2007","journal-title":"Farmacological Rep"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167131","article-title":"High TIM-3 expression may contribute to the functional impairment of bone marrow and circulating gamma delta T lymphocytes during the progression of multiple myeloma","volume":"140","author":"Corsale","year":"2022","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.763773","article-title":"Bone marrow-resident V\u03b41 T cells co-express TIGIT with PD-1, TIM-3 or CD39 in AML and myeloma","volume":"8","author":"Brauneck","year":"2021","journal-title":"Front Med"},{"key":"B79","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3324\/haematol.2013.092817","article-title":"Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"99","author":"Thiago","year":"2014","journal-title":"Haematologica"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001155","article-title":"Plasticity and heterogeneity in the generation of memory B cells and long-lived plasma cells: the influence of germinal center interactions and dynamics","volume":"185","author":"Good-Jacobson","year":"2010","journal-title":"J Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.5858\/133.10.1594","article-title":"Phenotyping studies of clonotypic B lymphocytes from patients with multiple myeloma by flow cytometry","volume":"133","author":"Conway","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0091-679X(01)63005-X","article-title":"A brief history of flow cytometry and sorting","volume":"63","author":"Melamed","year":"2001","journal-title":"Methods Cell Biol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41392-023-01380-0","article-title":"To metabolomics and beyond: a technological portfolio to investigate cancer metabolism","volume":"8","author":"Danzi","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1416-8","article-title":"An introduction to mass cytometry: fundamentals and applications","volume":"62","author":"Tanner","year":"2013","journal-title":"Cancer Immunology Immunother"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1351\/pac200880122627","article-title":"Flow cytometer with mass spectrometer detection for massively multiplexed single-cell biomarker assay","volume":"80","author":"Tanner","year":"2008","journal-title":"Pure Appl Chem"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/jid.2015.263","article-title":"Flow cytometry II: mass and imaging cytometry","volume":"135","author":"Doan","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.24300","article-title":"Platelet mass cytometry: Optimization of sample, reagent, and analysis parameters","volume":"99","author":"Spurgeon","year":"2021","journal-title":"Cytometry Part A"},{"key":"B88","doi-asserted-by":"crossref","DOI":"10.1002\/cyto.a.23664","article-title":"Implementation and validation of an automated flow cytometry analysis pipeline for human immune profiling","volume":"95","author":"Conrad","year":"2019","journal-title":"Cytometry Part A."},{"key":"B89","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1049\/iet-syb.2016.0016","article-title":"Recent omics technologies and their emerging applications for personalised medicine","volume":"11","author":"Kim","year":"2017","journal-title":"IET Syst Biol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2010.07.002","article-title":"Highly multiparametric analysis by mass cytometry","volume":"361","author":"Ornatsky","year":"2010","journal-title":"J Immunol Methods"},{"key":"B91","doi-asserted-by":"crossref","DOI":"10.1039\/C6JA00400H","article-title":"Characterization of a new ICP-TOFMS instrument with continuous and discrete introduction of solutions","volume":"32","author":"Hendriks","year":"2017","journal-title":"J Analytical Atomic Spectrometry."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3109\/07388551.2015.1128876","article-title":"Flow cytometry: basic principles and applications","volume":"37","author":"Adan","year":"2017","journal-title":"Crit Rev Biotechnol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/cyto.a.22778","article-title":"Platinum-conjugated antibodies for application in mass cytometry","volume":"89","author":"Mei","year":"2016","journal-title":"Cytometry Part A"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/bs.mie.2019.07.025","article-title":"Phenotyping of tumor infiltrating immune cells using mass-cytometry (CyTOF)","volume":"632","author":"Maby","year":"2020","journal-title":"Methods Enzymology"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1004583","article-title":"Using mass cytometry for the analysis of samples of the human airways","volume":"13","author":"Rocha-Hasler","year":"2022","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-1-4939-9454-0_5","article-title":"Scalable conjugation and characterization of immunoglobulins with stable mass isotope reporters for single-cell mass cytometry analysis","author":"Hartmann","year":"2019","journal-title":"Mass cytometry: Methods Protoc"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02367","article-title":"Minimizing batch effects in mass cytometry data","volume":"10","author":"Schuyler","year":"2019","journal-title":"Front Immunol"},{"key":"B98","first-page":"1","article-title":"Flow cytometry: definition, history, and uses in biological research","author":"Goetz","year":"2018","journal-title":"Flow Cytometry Basics Non-Expert"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00415","article-title":"Validation of CyTOF against flow cytometry for immunological studies and monitoring of human cancer clinical trials","volume":"9","author":"Gadalla","year":"2019","journal-title":"Front Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.v101.11","article-title":"A comparison of spectral unmixing to conventional compensation for the calculation of fluorochrome abundances from flow cytometric data","volume":"101","author":"Novo","year":"2022","journal-title":"Cytometry A"},{"key":"B101","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2015.06.001","article-title":"Impact of recent innovations in the use of mass cytometry in support of drug development","volume":"20","author":"Nassar","year":"2015","journal-title":"Drug Discov Today"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1191992","article-title":"Performance of spectral flow cytometry and mass cytometry for the study of innate myeloid cell populations","volume":"14","author":"van der Pan","year":"2023","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1038\/s41598-023-49145-7","article-title":"Quantum measurement enables single biomarker sensitivity in flow cytometry","volume":"14","author":"Sabines-Chesterking","year":"2024","journal-title":"Sci Rep"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-018-0016-7","article-title":"Metal-isotope-tagged monoclonal antibodies for high-dimensional mass cytometry","volume":"13","author":"Han","year":"2018","journal-title":"Nat Protoc"},{"key":"B105","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4939-9454-0_2","article-title":"Acquisition, processing, and quality control of mass cytometry data","author":"Lee","year":"2019","journal-title":"Methods Mol Biol. 1989"},{"key":"B106","article-title":"Development of a 43 color panel for the characterization of conventional and unconventional T-cell subsets, B cells, NK cells, monocytes, dendritic cells, and innate lymphoid cells using spectral flow cytometry","volume":"105","author":"Sahir","year":"2020","journal-title":"Cytometry A."},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.v97.10","article-title":"OMIP-069: forty-color full spectrum flow cytometry panel for deep immunophenotyping of major cell subsets in human peripheral blood","volume":"97","author":"Park","year":"2020","journal-title":"Cytometry A"},{"key":"B108","doi-asserted-by":"crossref","DOI":"10.1111\/ijlh.14098","article-title":"Full spectrum flow cytometry in the clinical laboratory","author":"Brestoff","year":"2023","journal-title":"Int J Lab Hematol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.v91.11","article-title":"Determination of background, signal-to-noise, and dynamic range of a flow cytometer: A novel practical method for instrument characterization and standardization","volume":"91","author":"Giesecke","year":"2017","journal-title":"Cytometry A."},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.04.019","article-title":"Mass cytometry: single cells, many features","volume":"165","author":"Spitzer","year":"2016","journal-title":"Cell"},{"key":"B111","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4939-3684-7_2","article-title":"Application of mass cytometry (CyTOF) for functional and phenotypic analysis of natural killer cells","volume":"1441","author":"Kay","year":"2016","journal-title":"Methods Mol Biol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3507","article-title":"High-resolution myogenic lineage mapping by single-cell mass cytometry","volume":"19","author":"Porpiglia","year":"2017","journal-title":"Nat Cell Biol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/cyto.a.24298","article-title":"Ab initio spillover compensation in mass cytometry data","volume":"99","author":"Miao","year":"2021","journal-title":"Cytometry A."},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2023.05.004","article-title":"Advances in clinical mass cytometry","volume":"43","author":"Koladiya","year":"2023","journal-title":"Clin Lab Med"},{"key":"B115","article-title":"Standardization and optimization of multiparameter intracellular cytokine staining","volume":"73","author":"Nomura","year":"2008","journal-title":"Cytometry A"},{"key":"B116","article-title":"Considerations for the control of background fluorescence in clinical flow cytometry","volume":"76","author":"Hulspas","year":"2009","journal-title":"Cytometry B Clin Cytom."},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1007\/BF02894264","article-title":"Enumeration of lymphocyte subsets using flow cytometry: Effect of storage before and after staining in a developing country setting","volume":"19","author":"Jalla","year":"2004","journal-title":"Indian J Clin Biochem"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.815828","article-title":"CyTOF((R)) for the masses","volume":"13","author":"Iyer","year":"2022","journal-title":"Front Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.768113","article-title":"How to prepare spectral flow cytometry datasets for high dimensional data analysis: A practical workflow","volume":"12","author":"den Braanker","year":"2021","journal-title":"Front Immunol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/cyto.a.23014","article-title":"Optimization of mass cytometry sample cryopreservation after staining","volume":"91","author":"Sumatoh","year":"2017","journal-title":"Cytometry A."},{"key":"B121","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/cyto.b.v63b:1","article-title":"Fixation and cryopreservation of whole blood and isolated mononuclear cells: Influence of different procedures on lymphocyte subset analysis by flow cytometry","volume":"63","author":"Pinto","year":"2005","journal-title":"Cytometry B Clin Cytom."},{"key":"B122","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1002\/ctm2.v10.6","article-title":"Progress and applications of mass cytometry in sketching immune landscapes","volume":"10","author":"Zhang","year":"2020","journal-title":"Clin Transl Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.v83a.5","article-title":"Generalized unmixing model for multispectral flow cytometry utilizing nonsquare compensation matrices","volume":"83","author":"Novo","year":"2013","journal-title":"Cytometry A"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1101\/2025.04.17.649396","article-title":"Measurement and prediction of unmixing-dependent spreading in spectral flow cytometry panels","author":"Mage","year":"2025","journal-title":"bioRxiv"},{"key":"B125","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-0716-3020-4_1","article-title":"Development of spectral imaging cytometry","volume-title":"Spectral and Imaging Cytometry: Methods and Protocols","author":"Vorobjev","year":"2023"},{"key":"B126","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1002\/eji.202170126","article-title":"Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)","volume":"51","author":"Cossarizza","year":"2021","journal-title":"Eur J Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.23693","article-title":"High-parameter mass cytometry evaluation of relapsed\/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of Action","volume":"95","author":"Adams","year":"2019","journal-title":"Cytometry A."},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.v81a.9","article-title":"FlowRepository: a resource of annotated flow cytometry datasets associated with peer-reviewed publications","volume":"81","author":"Spidlen","year":"2012","journal-title":"Cytometry A."},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2012.02.010","article-title":"A deep profiler's guide to cytometry","volume":"33","author":"Bendall","year":"2012","journal-title":"Trends Immunol"},{"key":"B131","doi-asserted-by":"crossref","DOI":"10.4132\/jptm.2017.09.05","article-title":"Aberrant CD3 expression in a relapsed plasma cell neoplasm","volume":"52","author":"Go","year":"2018","journal-title":"J Pathol Transl Med"},{"key":"B132","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/cytob.21173","article-title":"A case of CD138\u2013\/CD19+\/CD4+ IgD plasma cell leukemia","volume":"88","author":"Sorigue","year":"2015","journal-title":"Cytometry Part B: Clin Cytometry."},{"key":"B133","doi-asserted-by":"crossref","first-page":"100022","DOI":"10.1016\/j.jtauto.2019.100022","article-title":"CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients","volume":"2","author":"Frerichs","year":"2019","journal-title":"J Trans Autoimmunity."},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.09.020","article-title":"How long can we store blood samples: A systematic review and meta-analysis","volume":"24","author":"Wu","year":"2017","journal-title":"EBioMedicine"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2019.07.019","article-title":"Nucleic acid sensors and programmed cell death","volume":"432","author":"Maelfait","year":"2020","journal-title":"J Mol Biol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12860-020-00321-x","article-title":"A novel cell permeability assay for macromolecules","volume":"21","author":"Flores Bueso","year":"2020","journal-title":"BMC Mol Cell Biol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/bs.mie.2016.02.026","article-title":"ChIP-sequencing to map the epigenome of senescent cells using benzonase endonuclease","volume":"574","author":"Rai","year":"2016","journal-title":"Methods Enzymol"},{"key":"B138","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/imm.12706","article-title":"Isolation and high-dimensional phenotyping of gastrointestinal immune cells","volume":"151","author":"David","year":"2017","journal-title":"Immunology"},{"key":"B139","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1038\/s41467-022-31810-6","article-title":"The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance","volume":"13","author":"Ferguson","year":"2022","journal-title":"Nat Commun"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btw191","article-title":"flowAI: automatic and interactive anomaly discerning tools for flow cytometry data","volume":"32","author":"Monaco","year":"2016","journal-title":"Bioinformatics"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-022-02439-8","article-title":"Challenges in translational machine learning.","volume":"141","author":"Couckuyt","year":"2022","journal-title":"Hum Genet"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.v101.4","article-title":"PeacoQC: Peak-based selection of high quality cytometry data","volume":"101","author":"Emmaneel","year":"2022","journal-title":"Cytometry A."},{"key":"B143","doi-asserted-by":"crossref","DOI":"10.1002\/cyto.a.22935","article-title":"Standardization and quality control for high-dimensional mass cytometry studies of human samples","volume":"89","author":"Kleinsteuber","year":"2016","journal-title":"Cytometry Part A."},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02657","article-title":"Mass cytometry imaging for the study of human diseases\u2014applications and data analysis strategies","volume":"10","author":"Baharlou","year":"2019","journal-title":"Front Immunol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2022.116794","article-title":"Insights into highly multiplexed tissue images: A primer for Mass Cytometry Imaging data analysis","volume":"116794","author":"Zhao","year":"2022","journal-title":"TrAC Trends Analytical Chem"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-016-0178-1","article-title":"Validation of biomarkers to predict response to immunotherapy in cancer: volume I\u2014pre-analytical and analytical validation","volume":"4","author":"Masucci","year":"2016","journal-title":"J immunotherapy cancer."},{"key":"B147","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/2767-9764.CRC-23-0357","article-title":"Spectral Flow Cytometry Methods and Pipelines for Comprehensive Immunoprofiling of Human Peripheral Blood and Bone Marrow","volume":"4","author":"Spasic","year":"2024","journal-title":"Cancer Res Commun"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.v101.11","article-title":"Unlocking autofluorescence in the era of full spectrum analysis: Implications for immunophenotype discovery projects","volume":"101","author":"Jameson","year":"2022","journal-title":"Cytometry A."},{"key":"B149","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1038\/s41467-019-13055-y","article-title":"Automated optimized parameters for T-distributed stochastic neighbor embedding improve visualization and analysis of large datasets","volume":"10","author":"Belkina","year":"2019","journal-title":"Nat Commun"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btae179","article-title":"Efficient cytometry analysis with FlowSOM in Python boosts interoperability with other single-cell tools","volume":"40","author":"Couckuyt","year":"2024","journal-title":"Bioinformatics"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-9445-2_18","article-title":"Supervised machine learning with CITRUS for single cell biomarker discovery","volume":"1989","author":"Polikowsky","year":"2019","journal-title":"Methods Mol Biol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.23053","article-title":"Toward deterministic and semiautomated SPADE analysis","volume":"91","author":"Qiu","year":"2017","journal-title":"Cytometry A"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1642609\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T05:32:40Z","timestamp":1756963960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1642609\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":152,"alternative-id":["10.3389\/fimmu.2025.1642609"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1642609","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"article-number":"1642609"}}